Abstract
Antigens of Plasmodium falciparum targeted by most current and future vaccines are generally not conserved. There are limited studies estimating the risk of parasite selection with vaccines. We adapted an individual-based model of malaria to assess which conditions favour genotypes having some degree of vaccine resistance and estimate the impact of resistance spread on vaccine effectiveness. Even parasite genotypes with low degrees of vaccine resistance are likely to spread relatively quickly if vaccines are implemented in children and even faster in a broader population. However, only highly resistant genotypes could strongly reduce vaccine effectiveness. These results highlight that it is essential to understand the degree to which genotypes exhibit reduced sensitivity to vaccines and monitor genotype frequency and vaccine effectiveness along with vaccine deployment. If some genotypes exhibit reduced efficacy to vaccines, our results further suggest that polyvalent or combination vaccines should be considered to limit resistance spread.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded through the Swiss National Science Foundation Professorship grant of M.A.P. (PP00P3_203450).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
